Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients
2001
Increasing Paclitaxel Absorption with GF120918
Sample size: 6
publication
Evidence: moderate
Author Information
Author(s): Malingré M M, Beijnen J H, Rosing H, Koopman F J, Jewell R C, Paul E M, Huinink W W Ten Bokkel, Schellens J H M
Primary Institution: The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital
Hypothesis
Co-administration of GF120918 will increase the systemic exposure to oral paclitaxel in cancer patients.
Conclusion
The combination of oral paclitaxel with GF120918 significantly increases its systemic exposure and is well tolerated.
Supporting Evidence
- The mean AUC of paclitaxel after oral administration with GF120918 was 3.27 ± 1.67 μM.h.
- The mean AUC of paclitaxel with CsA was 2.55 ± 2.29 μM.h.
- The mean AUC after i.v. administration of paclitaxel was 15.92 ± 2.46 μM.h.
- GF120918 is a good and safe alternative for CsA.
Takeaway
This study found that a new drug, GF120918, helps patients absorb more of their cancer medicine, paclitaxel, when taken by mouth.
Methodology
Six patients received oral paclitaxel with GF120918 and their drug levels were measured.
Participant Demographics
Cancer patients
Statistical Information
Confidence Interval
3.27 ± 1.67 μM.h
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website